Treatment and prevention of acute exacerbation of chronic obstructive pulmonary disease with erdosteine
https://doi.org/10.18093/0869-0189-2015-25-3-373-377
Abstract
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) significantly reduce quality of life and increase a cost of disease treatment. Apart from antibiotics and bronchodilators, mucolytic agents play an important role in treatment and prevention of AECOPD. A literature review showed that erdosteine has significant antioxidant, antiadhesive, antiinflammatory and mucoregulatory properties and could effect clinical signs and symptoms of COPD. Use of erdosteine in patients with AECOPD could reduce durations of AECOPD, hospitalizations due to AECOPD and work-off periods.
About the Authors
A. V. Budnevskiy
State Institution «N.N.Burdenko Voronezh State Medical Academy», Healthcare Ministry of Russia: 10, Studencheskaya str., Voronezh, 394000, Russia
Russian Federation
Russian Federation
MD, Professor, Head of Department of General Internal Medicine, State Institution «N.N.Burdenko Voronezh State Medical Academy», Healthcare Ministry of Russia; tel.: (4732) 63-81-30;
A. V. Pertsev
State Institution «N.N.Burdenko Voronezh State Medical Academy», Healthcare Ministry of Russia: 10, Studencheskaya str., Voronezh, 394000, Russia
Russian Federation
Russian Federation
PhD student, Department of General Internal Medicine, State Institution «N.N.Burdenko Voronezh State Medical Academy», Healthcare Ministry of Russia; tel.: (4732) 63-81-30;
E. S. Ovsyannikov
State Institution «N.N.Burdenko Voronezh State Medical Academy», Healthcare Ministry of Russia: 10, Studencheskaya str., Voronezh, 394000, Russia
Russian Federation
Russian Federation
PhD, Associate Professor, Department of General Internal Medicine, State Institution «N.N.Burdenko Voronezh State Medical Academy», Healthcare Ministry of Russia; tel.: (473) 263-81-30;
References
1. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15–54.
2. Белевский А.С. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). Пер. с англ. М.: Российское респираторное общество; 2012.
3. Авдеев С.Н. Хроническая обструктивная болезнь легких: обострения. Пульмонология. 2013; 3: 5–19.
4. Авдеев С.Н. Новые возможности противовоспалительной терапии хронической обструктивной болезни легких. Пульмонология. 2013; 4: 95–101.
5. Будневский А.В., Овсянников Е.С., Чернов А.В. и др. Диагностическое значение биомаркеров системного воспаления при хронической обструктивной болезни легких. Клиническая медицина. 2014; 92 (9): 16–21.
6. Будневский А.В., Бурлачук В.Т., Перцев А.В. Компьютерная система мониторинга хронической обструктивной болезни легких. Пульмонология. 2014; 2: 69–72.
7. Будневский А.В., Овсянников Е.С., Чернов А.В. Прогностическое значение биомаркеров в оценке эффективности терапии хронической обструктивной болезни легких (обзор литературы). Молодой ученый. 2014; 65 (6): 284–287.
8. Hasegawa K., Tsugawa Y., Tsai C.-L. et al. Frequent utilization of the emergency department for acute exacerbation of chronic obstructive pulmonary disease. Respir. Res. 2014; 15: 40.
9. Yang H., Xiang P., Zhang E. et al. Predictors of exacerbation frequency in chronic obstructive pulmonary disease. Eur. J. Med. Res. 2014; 19: 18.
10. Csikesz N.G., Gartman E.J. New developments in the assessment of COPD: early diagnosis is key. Int. J. Chron. Obstruct. Pulm. Dis. 2014; (9): 277–286.
11. Wang Y., Stavem K., Dahl F.A. et al. Factors associated with a prolonged length of stay after acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Int. J. Chron. Obstruct. Pulm. Dis. 2014; 9: 99–105.
12. Punekar Y.S., Shukla A., Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int. J. Chron. Obstruct. Pulm. Dis. 2014; 9: 65–73.
13. Solem C.T., Sun S.X., Sudharshan L. et al. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 641–652.
14. Stafyla E. Chronic obstructive pulmonary disease exacerbation frequency and severity. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 533–535.
15. Moretti M., Bottrighi P., Dallari R. et al. The effect of long term treatment with erdosteine on COPD: The EQUALIFE Study. Drugs Exp. Clin. Res. 2004; 30:143.
16. Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Exp. Rev. Respir. Med. 2007; 1: 307–316.
17. Braga P.C., Dal Sasso M., Zuccotti T. Assessment of the antioxidant activity of the SH-metabolite 1 of erdosteine on human neutrophil oxidative bursts. Arzneim. Forsch. Drug Res. 2000; 50 (8): 739–746.
18. Dal Sasso M., Culici M., Bianchi T. et al. Inhibitory effects of metabolite 1 of erdosteine on the generation of nitric oxide and peroxynitrite chemiluminescence by human neutrophils. Pharmacology. 2004; 71: 120–127.
19. Hayashi H., Hosoe H., Kaise T., Ohmori K. Protective effects of Erdosteine against hypochlorus acid-induced acute lung injury and lipopolysaccharide-induced neutrophilic inflammation in mice. J. Pharm. Pharmacol. 2000; 52: 1411–1416.
20. Ege E., Ilhan A., Gurel A. et al. Erdosteine ameliorates neurological outcome and oxidative stress due to ischemia / reperfusion injury in rabbit spinal cord. Eur. J. Vasc. Endovasc. Surg. 2004; 28: 379–386.
21. Sener G., Sehirli A.O., Toklu H.Z. et al. Erdosteine treatment attenuates oxidative stress and fibrosis in experimental biliary obstruction. Pediatr. Surg. Int. 2007; 5: 123–126.
22. Sener G., Aksoy H.; Sehirli O et al. Erdosteine prevents colonic inflammation through its antioxidant and free radical scavenging activities. Dig. Dis. Sci. 2007; 52 (9): 2122–2132.
23. Dal Negro R.W., Visconti M., Trevisan F. et al. Erdosteine 600 mg, but not placebo and NAC 1200 mg, restores airways response to inhaled salbutamol 200 mcg in COPD. Eur. Respir. J. 2007; 30: 354.
24. Braga P.C., Zuccotti T., Dal Sasso M. Bacterial adhesiveness: effects of the SH-metabolite of Erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone. Chemotherapy. 2001; 47: 208–214.
Review
For citations:
Budnevskiy A.V., Pertsev A.V., Ovsyannikov E.S. Treatment and prevention of acute exacerbation of chronic obstructive pulmonary disease with erdosteine. PULMONOLOGIYA. 2015;25(3):373-377. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-3-373-377
Views:
2255
Email this article 